Patients with LVV and IBD present with distinct clinical characteristics, including earlier onset and more severe vascular involvement.

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.

Giant cell arteritis (GCA) is a chronic systemic vasculitis affecting large-sized and medium-sized vessels. Glucocorticoids are currently the mainstay of treatment for GCA and associated large vessel ...

It is the most common vasculitis affecting adults in western countries. White women over the age of 50 – most commonly between the ages of 70 and 80 years – have the highest risk of developing giant ...

Giant Cell Arteritis (GCA) Formerly called temporal arteritis, GCA is the most common form of vasculitis. It primarily affects white women and older adults (over 50), causing inflammation in the ...

Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the phase 3 MOTION trial. The FDA has approved vimseltinib (DCC-3014) for the ...

Autoimmune vasculitis is a group of conditions that cause blood vessel inflammation. Examples include Kawasaki disease and giant cell arteritis. They develop as a result of an overreaction of your ...

In this study, we have investigated how these luminal myofibroblasts develop during Kawasaki disease (KD), a paediatric vasculitis typically involving ... Takayasu’s arteritis and Giant Cell arteritis ...

When the large blood vessels develop vasculitis, it is an independent disease, such as Takayasu's or giant cell (also called cranial or temporal) arteritis. This type of vasculitis has completely ...

induces significant and sustained remission in people with new-onset or relapsing giant cell arteritis (GCA). The primary endpoint of sustained remission — the absence of GCA signs or symptoms ...